EpiBiologics

EpiBiologics is a venture-backed biotechnology company focused on developing next-generation protein degradation therapies. Their proprietary EpiTAC platform targets membrane and extracellular proteins, approximately 40% of the human proteome, which have been historically difficult to target with traditional drug approaches. This unique technology utilizes bispecific antibodies and a diverse library of tissue-specific degrader receptors to selectively degrade disease-driving proteins, offering a promising new therapeutic modality for a wide range of diseases.

EpiBiologics has established a strong leadership team with expertise in protein engineering, drug development, and business strategy. The company has secured significant funding, including over $70 million in Series A financing, which enables them to advance their pipeline of drug candidates, expand their platform, and build their talented team. EpiBiologics is headquartered in San Mateo, California, and is poised to become a leading player in the protein degradation field, delivering innovative and impactful treatments for patients in need.

EpiBiologics offers a flexible work environment, highlighted by their generous unlimited PTO policy, paid holidays, and a 10-week parental bonding leave. This suggests a company culture that values work-life balance and empowers employees to manage their schedules effectively.

EpiBiologics offers a competitive benefits package designed to support employee well-being. This includes comprehensive health insurance plans covering medical, vision, and dental, as well as life insurance. The company also provides competitive base pay, bonus potential, and an equity package. To promote work-life balance, they offer unlimited paid time off, paid holidays, a winter break, and 10 weeks of parental bonding leave. Additionally, they have a 401(k) plan to encourage employees to save for retirement.

EpiBiologics is a venture-backed biotechnology company focused on developing first-in-class and best-in-class antibody-based targeted therapies that degrade membrane and extracellular proteins, which are responsible for driving various diseases. The company's mission is to expand protein degradation technology to address these previously undruggable targets, thereby opening up new treatment possibilities for a wide range of disorders that currently lack effective therapies. By leveraging its proprietary EpiTAC platform and an extensive atlas of tissue-specific degrader receptors, EpiBiologics aims to create innovative medicines that can precisely target and eliminate disease-causing proteins in a tissue-selective manner, ultimately improving patient outcomes.

EpiBiologics fosters a collaborative and fast-paced work environment, prioritizing innovation and scientific excellence. The company values teamwork, open communication, and a passion for developing groundbreaking medicines. This dynamic startup atmosphere encourages employees to contribute to the company's mission of creating transformative therapies for patients in need.

EpiBiologics is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives and talents. They strive to create an environment where everyone has the opportunity to thrive and succeed, regardless of race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law. EpiBiologics actively seeks to attract and retain a diverse workforce and believes that a diverse and inclusive environment leads to better decision-making, stronger innovation, and a more positive and productive workplace.